Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1-T2* MRI contrast agent in U87MG cell detection.
Autor: | Ayyami Y; Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Ghorbani M; Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Iran Polymer and Petrochemical Institute, P.O.Box: 14965/115, Tehran, Iran., Dastgir M; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Malekzadeh R; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. reza.malek78@yahoo.com., Mortezazadeh T; Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. tmortezazadeh@gmail.com.; Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. tmortezazadeh@gmail.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | Magma (New York, N.Y.) [MAGMA] 2024 Oct; Vol. 37 (5), pp. 909-924. Date of Electronic Publication: 2024 May 25. |
DOI: | 10.1007/s10334-024-01169-4 |
Abstrakt: | Objective: Glioblastoma multiforme is a highly aggressive form of brain cancer, and early diagnosis plays a pivotal role in improving patient survival rates. In this regard, molecular magnetic resonance imaging has emerged as a promising imaging modality due to its exceptional sensitivity to minute tissue changes and the ability to penetrate deep into the brain. This study aimed to assess the efficacy of a novel contrast agent in detecting gliomas during MRI scans. Materials and Methods: The contrast agent utilized modified chitosan coating on manganese oxide nanoparticles. The modification included adding methotrexate and 5-aminolevulinic acid (MnO Results: The nanosystem was characterized and evaluated in MR imaging, safety, and ability to target cells both in vivo and in vitro. MTX-free nanoparticles (MnO Conclusion: This developed MnO (© 2024. The Author(s), under exclusive licence to European Society for Magnetic Resonance in Medicine and Biology (ESMRMB).) |
Databáze: | MEDLINE |
Externí odkaz: |